|
|
 |
|
 |
|
|
|
|
Title:
|
A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently with Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women with Locally Advanced Breast Cancer - IRB #09-22A
|
|
Treatments:
|
Cyclophosphamide, Doxorubicin, Paclitaxel, Pazopanib
|
|
Disease Site:
|
Breast
|
|
Disease SubSite:
|
Locally advanced or inflammatory
|
|
Drug Provided:
|
Pazopanib
|
|
Comments:
|
Investigators must be on the approval list below in order to enroll patients on this study.
|
|
Eligibility:
|
Prior to study entry, the local pathology department must have agreed to release the tumor block from the diagnostic biopsy sample. (Note: The tumor block from the diagnostic biopsy sample must be submitted within 60 days after study entry.) Patients must be female, Patients must be => 18 years old. The ECOG performance status must be 0 or 1 (see Appendix A), Patients must have the ability to swallow oral medication. The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy or limited incisional biopsy. Patients must have ER analysis performed on the primary tumor prior to randomization. If ER analysis is negative, then PgR analysis must also be performed. Patients are eligible with either hormone receptor-positive or hormone receptor-negative tumors. Patients must have clinical stage IIIA, IIIB, or IIIC disease (see Appendix B) with a mass in the breast or axilla measuring =>2.0 cm by physical exam, unless the patient has inflammatory breast cancer, in which case measurable disease by physical exam is not required. (Clinical staging should be based on the assessment by physical exam.
|
|
Participating Sites:
|
Northwest Cancer Specialists, Providence Milwaukie Hospital, Providence Portland Medical Center, Providence St. Vincent Medical Center, Southwest Washington Medical Center
|
|
|
|
|
 |
|
 |
|
|
|